Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis

키워드

참고문헌 (55)

1. Wolchok JD, "Nivolumab plus ipilimumab in advanced melanoma", N Engl J Med, 369, pp.122~133 (2013)
2. Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)
3. Ferris RL, "Nivolumab for recurrent squamous-cell carcinoma of the head and neck", N Engl J Med, 375, pp.1856~1867 (2016)
4. Yang Y, "Cancer immunotherapy : harnessing the immune system to battle cancer", J Clin Invest, 125, pp.3335~3337 (2015)
5. 박영민, "Nanoparticle-Based Vaccine Delivery for Cancer Immunotherapy", Immune Network, 13(5), pp.177~183 (2013), 대한면역학회
6. 김지성, "Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer Cells", Immune Network, 16(2), pp.99~108 (2016), 대한면역학회[DOI]
7. 손금주, "Immunogenic Cell Death Induced by Ginsenoside Rg3: Significance in Dendritic Cell-based Anti-tumor Immunotherapy", Immune Network, 16(1), pp.75~84 (2016), 대한면역학회[DOI]
8. Sanmamed MF, "A paradigm shift in cancer immunotherapy : from enhancement to normalization", Cell, 175, pp.313~326 (2018)
9. Sharma P, "Primary, adaptive, and acquired resistance to cancer immunotherapy", Cell, 168, pp.707~723 (2017)
10. Tumeh PC, "PD-1 blockade induces responses by inhibiting adaptive immune resistance", Nature, 515, pp.568~571 (2014)
11. 조주환, "Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles", Immune Network, 17(6), pp.378~391 (2017), 대한면역학회[DOI]
12. Noh KH, "Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype", Cancer Res, 72, pp.1717~1727 (2012)
13. Noh KH, "Nanog signaling in cancer promotes stem-like phenotype and immune evasion", J Clin Invest, 122, pp.4077~4093 (2012)
14. Song KH, "API5 confers cancer stem cell-like properties through the FGF2-NANOG axis", Oncogenesis, 6, pp.e285~ (2017)
15. Lee YH, "Gain of HIF-1α under normoxia in cancer mediates immune adaptation through the AKT", ERK and VEGFA axes, 2015, pp.21, 1438~1446
16. Oh SJ, "Targeting cyclin d-cdk4", 6 sensitizes immune-refractory cancer by blocking the scp3-nanog axis, 2018, pp.78, 2638~2653
17. Song KH, "Hdac1 upregulation by nanog promotes multidrug resistance and a stem-like phenotype in immune edited tumor cells", Cancer Res, 77, pp.5039~5053 (2017)
18. Song KH, "Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance", J Clin Invest, 128, pp.4098~4114 (2018)
19. 장한솔, "API5 induces cisplatin resistance through FGFR signaling in human cancer cells", Experimental and Molecular Medicine, 49, pp.1~10 (2017), 생화학분자생물학회
20. Woo SR, "Stabilization of HDAC1 via TCL1-pAKT-CHFR axis is a key element for NANOG-mediated multi-resistance and stem-like phenotype in immune-edited tumor cells", Biochem Biophys Res Commun, 503, pp.1812~1818 (2018)
21. Lee HJ, "NANOG signaling promotes metastatic capability of immunoedited tumor cells", Clin Exp Metastasis, 32, pp.429~439 (2015)
22. 송권호, "Apoptosis inhibitor 5 increases metastasis via Erk-mediated MMP expression", BMB Reports, 48(6), pp.330~335 (2015), 생화학분자생물학회
23. Schreiber RD, "Cancer immunoediting : integrating immunity’s roles in cancer suppression and promotion", Science, 331, pp.1565~1570 (2011)
24. O'Donnell JS, "Cancer immunoediting and resistance to T cell-based immunotherapy", Nat Rev Clin Oncol, 16, pp.151~167 (2019)
25. Schatton T, "Antitumor immunity and cancer stem cells", Ann N Y Acad Sci, 1176, pp.154~169 (2009)
26. Frank NY, "The therapeutic promise of the cancer stem cell concept", J Clin Invest, 120, pp.41~50 (2010)
27. Dean M, "Tumour stem cells and drug resistance", Nat Rev Cancer, 5, pp.275~284 (2005)
28. Lytle NK, "Stem cell fate in cancer growth, progression and therapy resistance", Nat Rev Cancer, 18, pp.669~680 (2018)
29. Wang ML, "Targeting cancer stem cells : emerging role of Nanog transcription factor", Onco Targets Ther, 6, pp.1207~1220 (2013)
30. Bussolati B, "Identification of a tumor-initiating stem cell population in human renal carcinomas", FASEB J, 22, pp.3696~3705 (2008)
31. Ezeh UI, "Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma", Cancer, 104, pp.2255~2265 (2005)
32. Hart AH, "The pluripotency homeobox gene NANOG is expressed in human germ cell tumors", Cancer, 104, pp.2092~2098 (2005)
33. Hoei-Hansen CE, "Stem cell pluripotency factor NANOG is expressed in human fetal gonocytes, testicular carcinoma in situ and germ cell tumours", Histopathology, 47, pp.48~56 (2005)
34. Lin T, "Overexpression of Nanog protein is associated with poor prognosis in gastric adenocarcinoma", Med Oncol, 29, pp.878~885 (2012)
35. Guo Y, "Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas", Histopathology, 59, pp.763~775 (2011)
36. Wen J, "Oct4 and Nanog expression is associated with early stages of pancreatic carcinogenesis", Pancreas, 39, pp.622~626 (2010)
37. Chiou SH, "Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma", Clin Cancer Res, 14, pp.4085~4095 (2008)
38. Zhou X, "Expression of the stem cell marker, Nanog, in human endometrial adenocarcinoma", Int J Gynecol Pathol, 30, pp.262~270 (2011)
39. Nagata T, "Prognostic significance of NANOG and KLF4 for breast cancer", Breast Cancer, 21, pp.96~101 (2014)
40. Lee M, "Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma", Int J Gynecol Cancer, 22, pp.1489~1496 (2012)
41. Chiou SH, "Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation", Cancer Res, 70, pp.10433~10444 (2010)
42. Han J, "RNA interference-mediated silencing of NANOG reduces cell proliferation and induces G0", G1 cell cycle arrest in breast cancer cells, 2012, pp.321, 80~88
43. Choi SC, "Nanog regulates molecules involved in stemness and cell cycle-signaling pathway for maintenance of pluripotency of P19 embryonal carcinoma stem cells", J Cell Physiol, 227, pp.3678~3692 (2012)
44. Bourguignon LY, "Hyaluronan-cd44 interaction activates stem cell marker nanog, stat-3-mediated mdr1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells", J Biol Chem, 283, pp.17635~17651 (2008)
45. Xu F, "Nanog : a potential biomarker for liver metastasis of colorectal cancer", Dig Dis Sci, 57, pp.2340~2346 (2012)
46. Tsai LL, "Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma", J Oral Pathol Med, 40, pp.621~628 (2011)
47. Siu MK, "Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers", Oncogene, 32, pp.3500~3509 (2013)
48. Biswas G, "Mechanism of mitochondrial stress-induced resistance to apoptosis in mitochondrial DNA-depleted C2C12 myocytes", Cell Death Differ, 12, pp.266~278 (2005)
49. Fulda S, "Targeting mitochondria for cancer therapy", Nat Rev Drug Discov, 9, pp.447~464 (2010)
50. Cuezva JM, "The bioenergetic signature of cancer : a marker of tumor progression", Cancer Res, 62, pp.6674~6681 (2002)
51. Isidoro A, "Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer", Biochem J, 378, pp.17~20 (2004)
52. Shin YK, "Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance", Cancer Res, 65, pp.3162~3170 (2005)
53. Liberti MV, "The Warburg effect : how does it benefit cancer cells", Trends Biochem Sci, 41, pp.211~218 (2016)
54. Vander Heiden MG, "Understanding the Warburg effect : the metabolic requirements of cell proliferation", Science, 324, pp.1029~1033 (2009)
55. Easwaran H, "Cancer epigenetics : tumor heterogeneity, plasticity of stem-like states, and drug resistance", Mol Cell, 54, pp.716~727 (2014)

관련 논문AI추천